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INTRODUCTION
Breast cancer imaging has improved dra-
matically over the last decade, with higher
and more uniform quality standards for
mammography, the increasinguse of sonog-
raphy and magnetic resonance imaging
(MRI), and the widespread availability of
imaging-guided percutaneous biopsy for
clinically occult disease. This review paper
describes the limitations that exist in the cur-
rent state of the art for breast cancer imaging
for detection and diagnosis. Four broad
areas of future investigation are described
in detail. First, we discuss the use of newer
versions of mammography, such as digital
mammography, with tomosynthesis and
digital subtraction mammography. Sec-
ondly, new screening for occult disease
might be improved through individualized
strategies that stratify by patient risk, for ex-
ample, through more rigorous screening
with new and different tools for women at
high risk. Third, the use of tools that might
be useful for less invasive therapy of breast
cancer with imaging to monitor the efficacy
of the therapy is discussed. Finally, we de-
scribe the use of imaging tomonitor and ad-
just neoadjuvant chemotherapy regimens in
the course of therapy for advanced breast
cancers when the risk of death is high.
NEW TYPES OF X-RAY MAMMOGRAPHY
Digital mammography holds great promise
for breast cancer screening, but to date,
the available results have been somewhat
mixed. One large screening trial showed sta-
tistically significantly improved specificity
with a nonstatistically significant lower sen-
sitivity for digital compared to traditional
filmmammography.1Another largeNorwe-
gian study showed no difference in cancer
detection rates between digital and film
mammography with worse specificity for
digital.2 These trials were limited in that
they included only one digital equipment
manufacturer, General Electric (General
Electric Medical Systems, Milwaukee, WI).
TheAmericanCollege ofRadiology Imaging
Network’s Digital Mammographic Imaging
Screening Trial (sponsored by the National
Cancer Institute), which enrolled 49,528
women in 34 centers in the United States
andCanada over a 24-month period, should
definitively determine how the sensitivity
and specificity of digital and filmmammog-
raphy compare in the screening setting
acrossmultiplemachine types. Those results
are expected in the spring of 2005. Table 1
presents a summary of the clinical trials
data on digital mammography.
Of course, there are other ways inwhich
digital mammography might allow im-
proved diagnostic accuracy compared to
film mammography. First, once mammog-
raphy is digital, tomography canmore easily
beperformed, at a dose that is comparable to
a two-view mammogram.3 This might be
an ideal tool for screening. Second, perhaps
the limitations of mammography in radio-
graphically dense breasts can be overcome
through the use of tomograms and three-
dimensional reconstructions. Third, per-
haps mammography can be performed
with less compression. Of course, clinical
trials are needed to prove these hypotheses.
To date, the General Electric tomosynthesis
system is being tested at Massachusetts
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GeneralHospital (Boston,MA) and theUniformedServices
Academy (Bethesda, MD). Other manufacturers (Hologic
Inc, Bedford, MA; and Sectra, Stockholm, Sweden) are
alsoworkingon tomography digital mammography prod-
ucts with various levels of mammographic compression,
dose, and visualization tools. There are currently no pub-
lished peer-reviewed papers describing clinical trials data
for tomosynthesis.
Another tool that might bring added value to digital
mammography for patients is digital subtraction angiogra-
phy.4,5 Two different methods for this technique have been
described. One uses intravenous contrast with a precontrast
image followed by a series of contrast-uptake images, with
the precontrast images subtracted digitally from the post-
contrast images and a contrast-uptake curve used for assess-
ment of potential malignancies, just as such curves are used
in MRI of the breast.4 The other method obtains images at
two different energy levels after the administration of an io-
dinated contrast agent with a weighted subtraction of the
logarithmic transform of these images, so as to create an im-
age that shows iodine.5 These methods have been demon-
strated to be feasible. Their effects on diagnostic accuracy
have yet to be carefully assessed, especially in comparison
to the more widely available MRI.
Another potential modality that is more easily used
with digital mammography than with film is computer-
assisted diagnosis and detection (CAD). For film, this tech-
nique is available only after digitization of the images. For
digital mammography, the CAD systems can be applied
more readily and easily to the raw digital data. One study
has demonstrated the sensitivity of R2 Image Checker (R2
Technologies, Sunnyvale, CA) with General Electric digital
mammograms (General Electric Medical Systems) in a test
set of 63 histologically proven cancers as 89% for calcifica-
tions and 81% for masses, slightly worse than this CAD
product performswithdigitizedfilmmammograms.6 Inad-
dition, there is evidence to believe that image processing
could further improve the visibility of lesions in digital
mammograms.7 Again, there are commercially available
systems that render second opinions of digital mammo-
grams. Unfortunately, to date, very little has been published
on thesemethods with digital mammography, and the util-
ity of CAD and image processing together has not been
widely utilized or explored. Clinical trials exploring these
adjunctive methods that are available with digital mam-
mography are definitely needed before these techniques
can be more broadly adopted.
EARLIER/BETTER BREAST CANCER DETECTION USING
SCREENING METHODS TAILORED TO INDIVIDUAL RISK
The report from the Institute of Medicine titled, Inte-
gration and Innovation: A Framework for Progress in
Early Detection and Diagnosis of Breast Cancer, is an
independent review that again shows screen-film mam-
mography to be the principal element of breast cancer
screening.8 Early detection of breast cancer by this
method has been shown to save lives over the last 40
years in seven screening trials in four countries, especially
for women older than 50 years of age.9 Despite the well-
known controversies about screening mammography,
particularly between the ages of 40 and 50 years, multiple
independent reviews of the literature agree that it is
a very useful way to look for breast cancer.10 Current ma-
jor reviewing organizations are the WHO International
Agency for Research on Cancer (March 2002), the Global
Mammography Summit (June 2002), and the US Pre-
ventive Health Task Force (September 2002).11,12 The
estimated screening-related decrease in mortality ranges
from 20% to 30%13 to 50% or more,14,15 with at least
some of the reduction in mortality undoubtedly due to
improvements in therapy.
The sensitivity estimates for screening mammography
are 83% to 95%, with specificity 90% to 98%.16With dense
breast tissue, sensitivity is lower, perhaps as low as 48%.17
Thus, many women with breast cancer are diagnosed only
after apalpablemass is locatedby thepatient herself, a family
member, or her physician. Since about 40,000 women and
400 men die of this disease each year in the United States,
according to theAmericanCancer Society, improved detec-
tion is clearly a necessary goal.18
The elimination of false positives at screening is also
essential, since now 10%9 to 50%19,20 of women screened
for 10 years will have an abnormal exam. The current widely
accepted US screening guidelines include all women 40
years and older, but there are some women who may not
need to be screened and some who need much better
screening methods than we now have. Low serum estradiol
Table 1. Clinical Trials Data on Digital Mammography
Lewin et al1 Skaane et al2 DMIST†
No. of participants
Digital 4,521 6,997 49,528
Film 4,521 17,911 49,528
Sensitivity, %
Digital 63 Not reported
Film 79 Not reported
Positive biopsy rate, %
Digital 28* Not reported








Area under the ROC curve
Digital 0.72 Not reported
Film 0.78 Not reported
Abbreviations: DMIST, Digital Mammographic Imaging Screening Trial;
ROC, receiver operating characteristic.
*Indicates a statistically significant difference.
†Results not presented or published yet.
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may safely exclude some from the general screening popu-
lation, whereas women with known risk factors could be
helped by improved tools.21 The American College of
Radiology Imaging Network (ACRIN) 6667 breast MRI
study has enrolled 1,007 women older than 18 years of
age who had a diagnosis of breast cancer in one breast
and a normal mammogram of the opposite breast. The
goal of that study is to determine the accuracy of MRI in
screening the opposite breast in this population. Other re-
cently published studies have demonstrated increased can-
cer detection in high risk women with breast MRI.22,23
ACRIN 6666, the Screening Breast Ultrasound Trial
for High-Risk Women, is assessing the utility of screen-
ing sonography in high-risk women. High risk is defined
in this trial as asymptomatic women over age 25 years
with heterogeneously or homogeneously dense breasts
by mammography who have a known BRCA1 or BRCA2
mutation, or a personal history of breast cancer, or a
prior biopsy showing lobular carcinoma-in-situ, aypical
ductal hyperplasia, atypical lobular hyperplasia or atyp-
ical papillary lesion who are not on chemoprevention,
or have a prior history of chest, mediastinal, or axillary
irradiation before age 30 years and at least 8 years before
study entry, or a lifetime risk of breast cancer by the
Gail or Claus models of at least 25%, or a 5-year risk
by the Gail model of at least 2.5%, or a 5-year risk by the
Gail model of at least 1.7% with at least 75% dense breast
tissue by a prior mammogram. More detailed informa-
tion on this trial, which is currently open to accrual,
can be found at the ACRIN Web site (www.acrin.org).
Serum proteomic markers and genetic tests may also
become useful for screening, as may the following imaging
tools: digital subtraction mammography, CAD/computer-
aided classification (CAC) capabilities, and tomosynthesis.
Someofthese toolsmaybeprovenandavailable ina fewyears.
NONSURGICAL TREATMENT OF EARLY/SMALL
BREAST CANCERS
Percutaneous ablation of these small cancers may be
possible using laser therapy, cryoablation, radiofrequency
ablation, microwave phased-array thermotherapy, and
high-intensity focused ultrasound (HIFU).
Laser therapy through a laser needle inserted under
local anesthesia, with stereotactic mammographic guid-
ance, showed 70% complete tumor ablation in one
study of 54 women with invasive and in situ breast
cancer. All had wire localization of residual tumor and
surgical excision.24
Sonographically guided cryoablation under local anes-
thesia has been successful for fibroadenomas.25 The experi-
ence with this technique for invasive breast cancers, limited
so far, gives reason for hope.25-28 This technique will need
evaluation in multiple centers, to include post-treatment
imaging with MRI and surgical/pathologic correlation.
Radiofrequency ablation is done through a 2-cm
probe, placed under ultrasound guidance, which sends
high-frequency alternating current into a breast mass.
Again, this procedure can be done with local anesthesia,
in outpatient clinics. Ten patients with invasive cancers
showed good tumor killing and pathologic-imaging corre-
lation on post-therapy MRI in a study reported by Burak
et al.29 Patients treated this way under general anesthesia
have shown similar results.30,31
For microwave phased-array thermotherapy, under
local anesthesia, a catheter is placed into the compressed
breast while the patient lies prone. Eight of the 10 patients
with larger cancers showed decrease in tumor size or
tumor necrosis in one study.32 Further study is needed,
correlated with post-treatment imaging.
MRI guidance is used for HIFU, with the high-
frequency ultrasound placed into the breast with no
need for invasive devices such as needles. One randomized
clinical trial included 48 women with invasive breast can-
cer and compared mastectomy to HIFU with subsequent
mastectomy.33 Another trial included 24 patients who
could not be treated surgically or who refused surgery,
showing correlation between residual tumor at core biopsy
and post-therapy MRI.34
So the future holds the possibility of less invasive
treatments for early/small breast cancers. How and how
much imaging will be involved in these treatments and
their monitoring is uncertain. So far, imaging has been
useful for correlation with surgical results. Effectiveness
of such therapies must be compared to the current stan-
dard treatments. Before certainty regarding the efficacy
of these therapies can be reached, further randomized
trials will be needed.
MONITORING BREAST CANCER THERAPY
RESULTS WITH IMAGING
MRI may have an important role in monitoring response
to therapy. MRI may help determine if a particular chemo-
therapy regimen is working for a patient, or if other drugs
should be tried. This is likely to be most useful in women
with locally advanced breast cancer or large tumors. In
such patients, clinical response to neoadjuvant chemother-
apy predicts for long-term outcome, for example, sur-
vival.35 It is conceivable that MRI could be better than
physical examination in monitoring response. ACRIN
6657/Cancer and Leukemia Group B (CALGB) Intergroup
Trial 49808, Contrast-Enhanced Breast MRI for Evalua-
tion of Patients Undergoing Neoadjuvant Chemotherapy
for Locally Advanced Breast Cancer, is evaluating the util-
ity of MRI in patients who are receiving an anthracycline-
based regimen only or followed by a taxane and enrolled in
CALGB correlative science study 150007. These women
undergo MRI at the time of diagnosis, after the anthracy-
cline therapy, and after the taxane therapy/before surgery.
Koomen et al
1676 JOURNAL OF CLINICAL ONCOLOGY
Copyright © 2005 by the American Society of Clinical Oncology. All rights reserved. 
Downloaded from www.jco.org at Med. Klinik d. Universitaet Heidelberg on April 8, 2005 . 
This use of MRI as a chemotherapy monitoring tool is
in its early stages. Those responding to their drug regimen
may show typical enhancement patterns over time. De-
creased MRI sensitivity during chemotherapy has also
been shown.36 Interpretation criteria for MRI during che-
motherapy may need to be quite different from prechemo-
therapy MRI. Published studies to date have included 30
or fewer patients.36-39 In the future, chemotherapy moni-
toring in this patient population may also include MRI
spectroscopy, positron emission tomography scanning
with new agents, digital mammography with contrast,
and sonography.
- - -
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